Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorAdvanced and/or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 159
- Registration Number
- NCT06724042
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
- Conditions
- Metastatic Malignant Solid TumorMalignant MesotheliomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 82
- Registration Number
- NCT06566079
- Locations
- 🇺🇸
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago, Illinois, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Conditions
- Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06445517
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Shanghai Jiao Tong University School of Medicine-Ruijin Hospital, Shanghai, Shanghai, China
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-11-05
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 80
- Registration Number
- NCT06414460
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven Breast Center, New Haven, Connecticut, United States
🇨🇳Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Study Evaluating ISM5411 Administered Orally to Healthy Volunteers
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 79
- Registration Number
- NCT06012578
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next